RETRA exerts anticancer activity in Ewing's sarcoma cells independent of their TP53 status.

Mutant p53 can exert oncogenic activity by inhibitory interaction with p73. The small-molecule RETRA has been described to disrupt this interaction and to suppress carcinoma cells (Kravchenko et al., 2008).